一种区分经典型与白血病样非结内型套细胞淋巴瘤并帮助预测结局的基因标签
研究在NanoString平台用19份纯化白血病样本训练出16基因L-MCL16检测,并在70例白血病样表现的套细胞淋巴瘤(MCL)独立队列中验证;该检测将37%病例归为白血病样非结内型MCL(nnMCL)、56%归为经典型MCL(cMCL),nnMCL的总生存优于cMCL,基因组复杂性与TP53/CDKN2A异常可预测更短生存。
要点
- L-MCL16检测可区分cMCL与nnMCL,预测随时间稳定。
- nnMCL的3年总生存为92%,cMCL为69%(P = .006)。
- 基因组复杂性和TP53/CDKN2A异常与更短总生存相关。
核心结论
- 新开发的L-MCL16检测能可靠识别白血病样本中MCL的两种分子亚型,结合遗传学异常可改善预后评估,并可能为管理决策提供有用的生物学信息。
研究设计与样本
- 研究在NanoString平台上用19份纯化白血病样本训练16基因检测(L-MCL16),并将锁定后的检测应用于70例白血病样表现的MCL患者独立队列。
主要发现
- L-MCL16检测将37%的病例归为nnMCL,56%归为cMCL。
- nnMCL与cMCL在结内表现、乳酸脱氢酶、免疫球蛋白重链基因突变状态、管理选择、基因组复杂性及CDKN2A/ATM缺失方面存在差异,但17p/TP53异常的比例在两个亚组中相似。
- 连续样本显示检测预测随时间保持稳定。
- nnMCL的总生存优于cMCL(3年总生存率92% vs 69%;P = .006),且至首次治疗时间更长。
- 基因组复杂性和TP53/CDKN2A异常可预测整个系列及cMCL中更短的总生存,而在nnMCL中仅基因组复杂性与更短的至首次治疗时间和总生存相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy, but some patients have a very indolent evolution. This heterogeneous course is related, in part, to the different biological characteristics of conventional MCL (cMCL) and the distinct subgroup of leukemic nonnodal MCL (nnMCL). Robust criteria to distinguish these MCL subtypes and additional biological parameters that influence their evolution are not well defined. We describe a novel molecular assay that reliably distinguishes cMCL and nnMCL using blood samples. We trained a 16-gene assay (L-MCL16 assay) on the NanoString platform using 19 purified leukemic samples. The locked assay was applied to an independent cohort of 70 MCL patients with leukemic presentation. The assay assigned 37% of cases to nnMCL and 56% to cMCL. nnMCL and cMCL differed in nodal presentation, lactate dehydrogenase, immunoglobulin heavy chain gene mutational status, management options, genomic complexity, and CDKN2A/ATM deletions, but the proportion with 17p/TP53 aberrations was similar in both subgroups. Sequential samples showed that assay prediction was stable over time. nnMCL had a better overall survival (OS) than cMCL (3-year OS 92% vs 69%; P = .006) from the time of diagnosis and longer time to first treatment. Genomic complexity and TP53/CDKN2A aberrations predicted for shorter OS in the entire series and cMCL, whereas only genomic complexity was associated with shorter time to first treatment and OS in nnMCL. In conclusion, the newly developed assay robustly recognizes the 2 molecular subtypes of MCL in leukemic samples. Its combination with genetic alterations improves the prognostic evaluation and may provide useful biological information for management decisions.
引用
- Clot G, Jares P, Giné E, et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood. 2018. PMID: 29769262. doi:10.1182/blood-2018-03-838136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。